founded in 2015, edesa biotech brings innovative new treatments for dermatological and anorectal diseases. late-stage prescription drugs developed by edesa biotech aim to help patients who experience limited treatment options. edesa biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.
Company profile
Ticker
EDSA
Exchange
Website
CEO
Pardeep Nijhawan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Stellar Biotechnologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
Edesa Biotech Research, Inc. • Edesa Biotech USA, Inc. ...
EDSA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
10-Q
2024 Q1
Quarterly report
9 Feb 24
8-K
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
9 Feb 24
10-K
2023 FY
Annual report
15 Dec 23
8-K
Edesa Biotech Reports Fiscal Year 2023 Results
15 Dec 23
8-K
Other Events
26 Oct 23
8-K
Entry into a Material Definitive Agreement
23 Oct 23
8-K
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
12 Oct 23
Latest ownership filings
4
Pardeep Nijhawan
2 Apr 24
4
Pardeep Nijhawan
25 Mar 24
4
Pardeep Nijhawan
1 Mar 24
4
Pardeep Nijhawan
2 Feb 24
SC 13G/A
Velan Capital Investment Management LP
29 Jan 24
SC 13D/A
Pardeep Nijhawan Medicine Professional Corp
16 Jan 24
4
Pardeep Nijhawan
12 Jan 24
SC 13D/A
Pardeep Nijhawan Medicine Professional Corp
21 Aug 23
4
Stephen Lemieux
4 Aug 23
4
Michael J Brooks
4 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm |
Cash burn (monthly) | 365.26 k | 144.13 k | 789.89 k | 768.56 k | 489.34 k | 553.04 k |
Cash used (since last report) | 2.50 mm | 985.88 k | 5.40 mm | 5.26 mm | 3.35 mm | 3.78 mm |
Cash remaining | 2.86 mm | 4.38 mm | -41.74 k | 104.13 k | 2.01 mm | 1.58 mm |
Runway (months of cash) | 7.8 | 30.4 | -0.1 | 0.1 | 4.1 | 2.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 4 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.27 bn |
Total shares | 6.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Pardeep Nijhawan Medicine Professional | 2.59 mm | $2.28 mm |
Lumira Capital Investment Management | 1.75 mm | $4.37 mm |
Velan Capital Investment Management | 1.28 mm | $809.98 mm |
CM Management | 417.60 k | $263.92 mm |
Vanguard | 110.86 k | $70.07 mm |
Geode Capital Management | 102.79 k | $64.26 mm |
CIBC World Markets | 54.63 k | $239.00 k |
STT State Street | 43.98 k | $27.48 mm |
NTRS Northern Trust | 22.54 k | $14.25 mm |
Tower Research Capital | 8.52 k | $5.39 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Nijhawan Pardeep | Common Shares | Grant | Acquire A | No | No | 0 | 3,253 | 0.00 | 111,063 |
25 Mar 24 | Nijhawan Pardeep | Common Shares | Buy | Acquire P | Yes | No | 4 | 5,000 | 20.00 k | 341,702 |
1 Mar 24 | Nijhawan Pardeep | Common Shares | Grant | Acquire A | No | No | 0 | 2,765 | 0.00 | 107,810 |
1 Feb 24 | Nijhawan Pardeep | Common Shares | Grant | Acquire A | No | No | 0 | 2,978 | 0.00 | 105,045 |
8 Jan 24 | Nijhawan Pardeep | Common Shares | Grant | Acquire A | No | No | 0 | 2,908 | 0.00 | 102,067 |
Press releases
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
11 Apr 24
Edesa Biotech to Participate in Upcoming Investor Conferences
2 Apr 24
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
21 Mar 24
Edesa Biotech to Participate in Upcoming Dermatology Meetings
4 Mar 24
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
9 Feb 24